Increased survival due to lower toxicity for high ‐risk T‐cell acute lymphoblastic leukemia patients in two consecutive pediatric‐inspired PETHEMA trials

ConclusionPatients with T ‐cell ALL included in the HR‐11 trial showed better OS than patients in the HR‐03, mostly driven by a reduction of NRM.

Source: European Journal of Haematology - November 22, 2018 Category: Hematology Authors: Pere Barba, Mireia Morgades, Pau Montesinos, Cristina Gil, Mar ía‐Laura Fox, Juana Ciudad, María‐José Moreno, José González‐Campos, Eulàlia Genescà, Daniel Martínez‐Carballeira, Rodrigo Martino, Susana Vives, Ramon Guardia, Sa Tags: ORIGINAL ARTICLE Source Type: research